moves to amend H.F. No. 1818 as follows:
Page 1, line 20, delete "12" and insert "six"
Page 2, line 6, delete "12" and insert "six"
Page 4, line 20, before "Sections" insert "(a)"
Page 4, after line 34, insert:
"(b) Nothing in sections 152.22 to 152.38 requires the medical assistance and
MinnesotaCare programs to reimburse an enrollee or a provider for costs associated with
the medical use of marijuana."
Page 5, line 31, after "marijuana" insert ", in compliance with the United States
Poison Prevention Packing Act regarding child resistant packaging and exemptions for
packaging for elderly patients"
Page 5, line 33, delete "and"
Page 5, line 36, delete the period and insert "; and"
Page 5, after line 36, insert:
"(8) establishing reasonable restrictions relating to signage, market, display, and
advertising of marijuana for medical use."
Page 7, line 5, before "The" insert "A county with an area greater than 5,000 square
miles must have at least two medical marijuana dispensaries, regardless of population."
Page 8, line 5, delete "15" and insert "the lesser of 30" and after "miles" insert "
or 30 minutes"
Page 17, line 32, delete "12" and insert "six"
Page 20, line 34, delete "2013" and insert "2014"
Page 21, lines 2, 6, and 13, delete "2013" and insert "2014"
Page 21, after line 33, insert:
"Sec. 20. Minnesota Statutes 2012, section 256B.0625, subdivision 13d, is amended to
read:

Sec. 20.

03/04/14 09:31 AM HOUSE RESEARCH JO/SK H1818A6

2.1	Subd. 13d. Drug formulary. (a) The commissioner shall establish a drug
2.2	formulary. Its establishment and publication shall not be subject to the requirements of the
2.3	Administrative Procedure Act, but the Formulary Committee shall review and comment
2.4	on the formulary contents.
2.5	(b) The formulary shall not include:
2.6	(1) drugs, active pharmaceutical ingredients, or products for which there is no
2.7	federal funding;
2.8	(2) over-the-counter drugs, except as provided in subdivision 13;
2.9	(3) drugs or active pharmaceutical ingredients used for weight loss, except that
2.10	medically necessary lipase inhibitors may be covered for a recipient with type II diabetes;
2.11	(4) drugs or active pharmaceutical ingredients when used for the treatment of
2.12	impotence or erectile dysfunction;
2.13	(5) drugs or active pharmaceutical ingredients for which medical value has not
2.14	been established; and
2.15	(6) drugs from manufacturers who have not signed a rebate agreement with the
2.16	Department of Health and Human Services pursuant to section 1927 of title XIX of the
2.17	Social Security Act; and
2.18	(7) marijuana for medical use as defined in sections 152.22 to 152.39.
2.19	(c) If a single-source drug used by at least two percent of the fee-for-service
2.20	medical assistance recipients is removed from the formulary due to the failure of the
2.21	manufacturer to sign a rebate agreement with the Department of Health and Human
2.22	Services, the commissioner shall notify prescribing practitioners within 30 days of
2.23	receiving notification from the Centers for Medicare and Medicaid Services (CMS) that a
2.24	rebate agreement was not signed."
2.25	Page 22, line 5, delete "2013" and insert "2014"
2.26	Renumber the sections in sequence and correct the internal references

Sec. 20. 2

Amend the title accordingly

2.27